Citadel Advisors
DAWN

Citadel Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Citadel Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.37M Hold
157,000
– – ﹤0.01% 5028
2025
Q4 		$1.46M Buy
+157,000
New +$1.31M ﹤0.01% 6564
2025
Q3 		– Sell
-23,500
Closed -$153K – 12961
2025
Q2 		$153K Sell
23,500
-45,500
-66% -$313K ﹤0.01% 10940
2025
Q1 		$547K Sell
69,000
-13,000
-16% -$140K ﹤0.01% 8282
2024
Q4 		$1.04M Buy
82,000
+56,300
+219% +$783K ﹤0.01% 6927
2024
Q3 		$358K Sell
25,700
-20,500
-44% -$292K ﹤0.01% 8940
2024
Q2 		$637K Buy
46,200
+25,800
+126% +$377K ﹤0.01% 7548
2024
Q1 		$337K Buy
20,400
+5,200
+34% +$77.8K ﹤0.01% 9216
2023
Q4 		$222K Sell
15,200
-300
-2% -$3.64K ﹤0.01% 9739
2023
Q3 		$190K Buy
15,500
+2,300
+17% +$30K ﹤0.01% 9996
2023
Q2 		$158K Sell
13,200
-700
-5% -$9.14K ﹤0.01% 10262
2023
Q1 		$186K Buy
13,900
+8,100
+140% +$158K ﹤0.01% 10306
2022
Q4 		$125K Sell
5,800
-8,200
-59% -$168K ﹤0.01% 10884
2022
Q3 		$280K Sell
14,000
-7,000
-33% -$149K ﹤0.01% 9724
2022
Q2 		$376K Buy
+21,000
New +$217K ﹤0.01% 9281

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Citadel Advisors's DAWN Position: Q1 2026 in Review

Citadel Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 1,359,613 shares — an estimated $19.2M sold.

Citadel Advisors first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $12.7M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Citadel Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,359,613 Day One Biopharmaceuticals shares in Q1 2026, an estimated $19.2M.
  • Citadel Advisors first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Citadel Advisors's Day One Biopharmaceuticals position peaked at $12.7M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.